Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.73 (urokinase-type plasminogen activator)
 10,685 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Methods for measuring antigen and activity of plasminogen activators (t-PA, u-PA), plasminogen activator inhibitors (PAI-1, PAI-2) and their complex have been improved in the past few years, but few comparative data are available and they should be standardized. In particular the commercial kits for determination of PAI-1 activity seem to be not accurate for the measurement of PAI-1 in plasma. The amount of generated plasmin can be measured as plasmin-alpha-2-antiplasmin complex (PAP). There are also some new tests which could differentiate between fibrinogenolysis (FgDP) and fibrinolysis (FnDP, D-dimer) as between primary and secondary activation of fibrinolysis (B beta 15-42 peptide). Normal D-dimer plasma concentration allows for the ruling out of venous thromboembolism with high probability, but the specificity of this tests is poor.
Acta Haematol Pol 1995
PMID:[Progress in the detection of intravascular activation of fibrinolysis]. 774 60

Five new dipeptides containing epsilon-aminocaproic acid were synthesized. All dipeptides markedly inhibit fibrinolytic activity of plasmin but only in low concentration (0.0002M). In higher concentration fibrinolytic activity was observed. Activity of dipeptides containing epsilon-aminocaproic acid, which antifibrinolytic activity is known, was tested on plasmin, thrombin, urokinase and euglobulin fraction using synthetic substrates.
Acta Pol Pharm 1994
PMID:Synthesis and activity of dipeptides containing epsilon-aminocaproic acid. 776

The aim of this study was to compare the secretory response of the vascular wall in vivo to DDAVP (i.v. 0.3 microgram/kg, 30 min) and to venous occlusion (VO, 20 min) in control healthy subjects, patients with von Willebrand's disease type I (vWd I) and patients with von Willebrand's disease type III (vWd III). In controls (n = 10) and vWd I (n = 12), DDAVP induced a 2 to 3-fold rise in plasma von Willebrand factor antigen (vWf: Ag), factor VIII coagulant activity (VIII: C) and tissue--type plasminogen activator antigen (t-PA:Ag). VO was less effective in increasing vWf: Ag and VIII:C but produced a greater rise in t-PA:Ag. Large increments (over 10-fold) were observed in plasmin-alpha 2-antiplasmin complexes following both stimuli. In vWd III (n = 10), DDAVP and VO failed to increase vWf:Ag, VIII:C and t-PA:Ag. No significant changes in plasmin-alpha 2-antiplasmin complexes were observed in this group. Moreover, the baseline t-PA:Ag values were significantly lower in vWd III (2.17 +/- 1.13 ng/ml) than in controls (4.84 +/- 1.97 ng/ml, p < 0.001). A significant increase in urokinase--type plasminogen activator antigen (u-PA:Ag) was found only in controls after VO. Neither controls nor patients with vWd showed any changes in plasma fibronectin levels following DDAVP. The low t-PA:Ag results and the abnormal fibrinolytic response to DDAVP and VO in patients with severe (type III) vWd indicate that their endothelial cell abnormality is more extensive than the defect in the synthesis or release of vWf.
Acta Haematol Pol 1994
PMID:Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease. 799 99

Plasminogen activator inhibitor-1 (PAI-1) plays particularly important role in regulation of homeostasis of fibrinolytic system. It neutralizes active molecules of tissue-type and urokinase-type plasminogen activators. PAI-1 is synthesized mainly in endothelial cells but it is present also in other cells. It was found in vitro that elevated expression of PAI-1 gene and increase in PAI-1 concentration released from endothelium is caused by many different biologically active substances. Among them there are thrombin, lipopolysaccharides, cell growth factors, cytokines and also glucocorticoids and phorbol esters. In this work mechanisms of regulation of PAI-1 synthesis and role of this protein in homeostasis of fibrinolytic system are described.
Acta Haematol Pol 1994
PMID:[Progress in knowledge about fibrinolysis regulation]. 799 70

Fifteen children treated with fibrinolytic agents are presented. The most frequent indication was thromboembolic disease (TED). Eleven patients received streptokinase, 5-urokinase and 3-tissue plasminogen activator. Concomitant heparin was administered to 9 patients with TED. Total resolution was achieved in 9 children, partial improvement in 5; 1 child died during treatment without any improvement. Bleeding complications were observed in 6 patients, 1 of them died due to haemorrhagic stroke. According to the literature and our own experience, we recommend fibrinolytic agents as the treatment of choice for severe TED also in children.
Pediatr Pol 1996 May
PMID:[One center's experience with fibrinolytic treatment in children]. 871 Apr 28

Suppression of the fibrinolytic activity plays an important role in the prevention of hemorrhage during pregnancy and labor. A hypofibrinolytic and hypercoagulable state may be established in the placenta during pregnancy. However, little infraction is present in the normal placenta. This evidence shows that placenta maintains the fibrinolytic activity in spite of hypercoagulable state. As there is a high amount of APC in the placenta, APC is thought to be involved in fibrinolysis of placenta. Thus, we studied the role of APC on fibrinolysis in placenta. (1) uPA activity of cell membrane reappears after incubation with uPA/PAI-1 complex and a large amount of APC by flow cytometry, (2) APC was made PAI-1/APC complex after incubation of uPA/PAI-1 complex with APC. Our results suggest that APC is the important substance for fibrinolysis in the placenta by decreasing of PAI activity.
Pol J Pharmacol
PMID:Relationship of urokinase type plasminogen activator, plasminogen activator inhibitor type 1 and activated protein C in fibrinolysis of human placenta. 911 54

Plasminogen activators and inhibitors regulate a variety of physiological and pathological processes involved in tissue morphogenesis, cell differentiation, migration, cancer cell invasion and metastasis. Several reports have shown the decrease of fibrinolytic activity in the blood of cancer patients. In this study we measured the concentrations of tissue plasminogen activator (t-PA), urokinase plasminogen activator (u-PA), activity of plasminogen activator inhibitor type 1 (PAI-1) and euglobulin lysis time (ELT) in the blood of 20 men aged 42-75 years old with planoepitheliale larynx carcinoma, and 10 healthy persons in similar age. In this study the mean values of t-PA, u-PA concentrations, PAI-1 activity and ELT in the blood of patients with larynx carcinoma were similar to the examination results of healthy persons, but 40% of our cancer patients have increased activity of PAI-1.
Otolaryngol Pol 1995
PMID:[Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms]. 945 29

Clinical and experimental studies suggest that urokinase plasminogen activator/u-PA/ is associated with cancer invasion and metastasis. The aim of study was to evaluate the concentration and activity of u-PA in the plasma of patients with planoepithelial lung carcinoma. The examined group consisted of 40 patients/33 men, 7 women/aged 58 years with lung cancer in II, IIIa and IIIb stage of disease and 30 healthy adults as control. In citrate plasma concentration and activity of u-PA with ELISA method were performed. Concentration of u-PA was significantly lower in cancer patients then in controls. No associations between sex, age and plasma levels of u-PA were observed. Concentration and activity of u-PA in patients with IIIb stage of cancer were significantly decreased in comparison to patients with IIIa stage.
Pneumonol Alergol Pol 1998
PMID:[Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer]. 985 63

A survey of literature has been presented relating to fibrinolytic substances secreted by malignant tumors, and the role of those substances in the progression of cancer. Particular attention has been given to the effects of plasmin proteolysis which is generated in the extracellular matrix by urokinase plasminogen activator (uPA) complexed with its receptor (uPAR). The paper also discusses the usefulness of the markings of the substances under discussion for diagnostic-prognostic purposes, and a perspective of using the new research in therapy, for example, by using antibodies anti-uPA and anti-uPAR.
Ginekol Pol 1999 Feb
PMID:[Fibrinolytic substances formation by cancer. Pathogenetic sequelae]. 1034 17

Forty one patients with recently recognised bronchial asthma were studied. Activity of plasminogen activator inhibitor (PAI-1), platelet adhesion and aggregation, antigens of tissue and urokinase plasminogen activators (respectively, t-PA Ag and u-PA Ag), euglobulin lysis time (ELT), complexes of plasmin-antiplasmin (PAP) and fibrin degradation products (FDP) were tested before and after fourteen days administration of 20-30 mg/d prednisone. Statistical significant increase of PAI-1 activity, on the average about 75%, was found (8.35 +/- 9.38 U/ml before, and 14.6 +/- 13.3 U/ml after treatment; p < 0.02). In 31 asthmatic patients (75.6%), after prednisone treatment, increased of PAI-1 activity together with platelet adhesion and aggregation were observed. Among other studied fibrinolysis factors no statistical significant differences before and after treatment were found. These results suggest that in asthmatic patients after prednisone treatment raises PAI-1 activity, probability because of releasing of the increased amount of PAI-1 from activated platelet.
Pol Merkur Lekarski 2000 Jan
PMID:[Fibrinolytic system in bronchial asthma after prednisone treatment]. 1076 44


1 2 Next >>